The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500. Detects a band of approximately 86 kDa (predicted molecular weight: 86 kDa).
Application notesIs unsuitable for Flow Cyt,ICC,IHC-P or IP.
FunctionKey dowstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion. The majority of beta-catenin is localized to the cell membrane and is part of E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton.
Tissue specificityExpressed in several hair follicle cell types: basal and peripheral matrix cells, and cells of the outer and inner root sheaths. Expressed in colon.
Involvement in diseaseDefects in CTNNB1 are associated with colorectal cancer (CRC) [MIM:114500]. Note=Activating mutations in CTNNB1 have oncogenic activity resulting in tumor development. Somatic mutations are found in various tumor types, including colon cancers, ovarian and prostate carcinomas, hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant embryonal tumors mainly affecting young children in the first three years of life. Defects in CTNNB1 are a cause of pilomatrixoma (PTR) [MIM:132600]; a common benign skin tumor. Defects in CTNNB1 are a cause of medulloblastoma (MDB) [MIM:155255]. MDB is a malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. Defects in CTNNB1 are a cause of susceptibility to ovarian cancer (OC) [MIM:167000]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. Note=A chromosomal aberration involving CTNNB1 is found in salivary gland pleiomorphic adenomas, the most common benign epithelial tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1.
Sequence similaritiesBelongs to the beta-catenin family. Contains 12 ARM repeats.
Post-translational modificationsPhosphorylation by GSK3B requires prior phosphorylation of Ser-45 by another kinase. Phosphorylation proceeds then from Thr-41 to Ser-37 and Ser-33. EGF stimulates tyrosine phosphorylation. Phosphorylation on Tyr-654 decreases CDH1 binding and enhances TBP binding. Ubiquitinated by the SCF(BTRC) E3 ligase complex when phosphorylated by GSK3B, leading to its degradation. Ubiquitinated by a E3 ubiquitin ligase complex containing UBE2D1, SIAH1, CACYBP/SIP, SKP1, APC and TBL1X, leading to its subsequent proteasomal degradation.
Cellular localizationCytoplasm. Nucleus. Cytoplasm > cytoskeleton. Cell junction > adherens junction. Cell junction. Cell membrane. Cytoplasmic when it is unstabilized (high level of phosphorylation) or bound to CDH1. Translocates to the nucleus when it is stabilized (low level of phosphorylation). Interaction with GLIS2 and MUC1 promotes nuclear translocation. Interaction with EMD inhibits nuclear localization.
Dot Blot - Anti-beta Catenin (phospho S37) antibody [EP742(2)Y] (ab75777)
Dot blot analysis of Beta catenin phospho peptide with ab75777 at 1/1000 exposed for 3 minutes. Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) (1/100,000) was used as the secondary antibody. Blocking buffer 5% NFDM/TBST. Diluting buffer 5% NFDM/TBST.
Lane 1: Beta catenin (pS33+pS37) phospho peptide Lane 2: Beta catenin (pS33) phospho peptide Lane 3: Beta catenin (pS37) phospho peptide Lane 4: Beta catenin non-phospho peptide
Western blot - Anti-beta Catenin (phospho S37) antibody [EP742(2)Y] (ab75777)
All lanes : Anti-beta Catenin (phospho S37) antibody [EP742(2)Y] (ab75777) at 1/500 dilution
Lane 1 : 293T cell lysates, untreated Lane 2 : 293T cell lysates, treated with calyculin A
Lysates/proteins at 10 µg per lane.
Secondary goat anti-rabbit HRP at 1/2000 dilution
Predicted band size : 86 kDa Observed band size : 86 kDa
References for Anti-beta Catenin (phospho S37) antibody [EP742(2)Y] (ab75777)
This product has been referenced in:
Zhang J et al. SOX4 inhibits GBM cell growth and induces G0/G1 cell cycle arrest through Akt-p53 axis. BMC Neurol14:207 (2014).
Read more (PubMed: 25366337) »
Li WF et al. WISP-1 contributes to fractionated irradiation-induced radioresistance in esophageal carcinoma cell lines and mice. PLoS One9:e94751 (2014).
Read more (PubMed: 24728101) »